Swiss Rockets secured an exclusive global license (ex‑Asia‑Pacific) to MGI/Complete Genomics’ CoolMPS technology and announced plans to launch CoolMPS‑based sequencers next year. The Basel‑based holding company said it will rely on Complete Genomics and MGI expertise to develop instrumentation and position itself as a western supplier of the chemistry-driven sequencing approach. The deal grants perpetual rights outside Asia‑Pacific and includes an option to expand into APAC in 2026. Swiss Rockets framed the move as strategic for multiomics and cancer diagnostics; the licensing decision has implications for NGS competition beyond established Illumina/MGI dynamics.